| ￥3500 | |
| Z05907-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 62.08 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 75-105 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Immobilized TPBG/5T4 hFc Chimera, Human, hFc Tag at 1 μg /ml (100 μl/well) on the plate. Dose response curve for Biotinylated Anti-TPBG Antibody, hFc Tag with the EC50 of 42.2ng/ml determined by ELISA. »
The purity of TPBG/5T4 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC. »
TPBG/5T4 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | The oncofetal tumor-associated antigen 5T4 (TBGP) has been linked with CSC properties in several different malignancies. 5T4 has functional attributes that are relevant to the spread of tumors including through EMT, CXCR4/CXCL12, Wnt, and Hippo pathways which may all contribute through the mobilization of CSCs. |
| Synonyms | M6P1; 5T4AG; WAIF1; TPBG; 5T4 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
